3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
39
Nivolumab
13
Cisplatin
12
Paclitaxel
11
Docetaxel
11
Carboplatin
10
atezolizumab
9
Trastuzumab
9
Gemcitabine
9
Cyclophosphamide
8
fludarabine
7
Bevacizumab
7
aldesleukin
6
durvalumab
5
Taxes
5
Oxaliplatin
5
Magnetic Resonance Spectroscopy
5
Leucovorin
5
Irinotecan
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
avelumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Ipilimumab
4
Drug Therapy
4
Cetuximab
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
tislelizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
bempegaldesleukin
×
Thoracic
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts